Clinical Trials | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Subscribe To Our Newsletter & Stay Updated
